Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119

Benzinga Newsdesk www.benzinga.com Negative 88.5%

Neg 88.5% Neu 0% Pos 0%

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $120 to $119.